Indicated Prevention of Schizophrenia

Klinik für Psychiatrie und Psychotherapie, Universität zu Köln, Kerpener Strasse 62, Köln, Germany.
Deutsches Ärzteblatt International (Impact Factor: 3.61). 08/2008; 105(30):532-9. DOI: 10.3238/arztebl.2008.0532
Source: PubMed

ABSTRACT Despite recent advances in their treatment, schizophrenic disorders are still among the diseases that most severely impair patients' quality of life. For this reason, centers for the early recognition of schizophrenic disorders have come into existence worldwide. In these centers, much effort is devoted to the development and testing of suitable preventive strategies.
In this article, we selectively review the literature on the currently available means of assessing the individual risk of becoming ill with schizophrenia and of preventing the imminent onset of the disease.
The currently recognized neurobiological and psychosocial risk factors are not predictive enough to enable the development and application of selective prevention measures for asymptomatic persons at risk. The imminent onset of schizophrenia can be predicted with high accuracy, however, in cases where an initially non-psychotic patient develops early cognitive symptoms that imply a risk of schizophrenia and then, later on in the prodrome of the disease (which typically lasts about five years), goes on to develop high-risk symptoms with mild psychosis. At this point, a differential strategy of indicated prevention can be put into action, including cognitive behavioral therapy, atypical antipsychotics in low doses, and neuroprotective agents.
The current state of knowledge in this innovative field of research leads us to expect that it will soon be possible to offer individually tailored preventive measures to persons seeking medical help and advice because of the early warning signs of schizophrenia.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Schizophrenia undoubtedly has an inheritable component and some genes for susceptibility for schizophrenia have been discovered. An intriguing question is whether there is any coherence between the function of these genes and neurotransmitter dysfunction in schizophrenia, such as dopamine and serotonin hyperactivity as well as glutamate and GABA hypoactivity in the mesolimbic system. The genes neuregulin-1 and dysbindin-1 are linked to glutamate hypoactivity. The gene encoding reduced COMT activity causes increasing dopamine activities due to a weaker inhibition of its deactivation. The gene GAD 67 results in reduced GABA function. Regarding neurotransmitter dysfunction, NMDA antagonists cause schizophrenia-like behaviour in experimental animals, which can be relieved by 5-HT2A antagonists. The neuronal combination in the mesolimbic system of healthy subjects could be that dopaminergic neurons would transmit a postsynaptic excitatory impulse to glutaminergic neurons, which would then inhibit serotonergic neurons presynaptically. These neurons, in turn, would transmit a postsynaptic excitatory impulse to GABAergic neurons, which would inhibit dopaminergic neurons presynaptically. The presynaptic inhibition of either GABA or glutamate prevents hyperactivity of either dopamine or serotonin. In animal experiments, it has been shown that 5-HT2A receptors are localized directly on dopaminergic cells in certain brain regions. In schizophrenia, decreasing or missing presynaptic inhibition by NMDA receptors leads to serotonin hyperactivity in the mesolimbic system and a decreasing or missing presynaptic function of GABA at GABAA receptors leads to increasing dopamine levels. In order to consider the function of susceptibility genes and neurotransmitter dysfunction, it has been shown that glutamate hypoactivity is encoded by the neuregulin-1 and dysbindin-1 genes and GABA hypoactivity in the GAD 67 gene. Decreased COMT activity enhances dopamine levels in the mesolimbic system. Thus, to improve the treatment of schizophrenia, it is important to develop atypical neuroleptics with an optimal ratio of 5-HT2A/D2 receptor occupancy and to examine whether agonism at the GABAA and NMDA receptor levels might improve the treatment of schizophrenic symptoms.
    Clinical Neurophysiology 03/2006; 37(01). DOI:10.1055/s-2006-939324 · 2.98 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Schizophrenia is a chronic and disabling mental disorder characterized by positive, negative and mood symptoms, disturbed coping abilities with elevated distress and a significant decline in cognition, quality of life and psychosocial functioning. About one-third of all patients with schizophrenia do not respond adequately to drug treatment. Today neuroscience and clinical research have sufficiently advanced to introduce a novel generation of compounds with neuroprotective properties. The use of neuroprotective agents in schizophrenia is not yet significantly established. An in-depth review of new compounds such as neurosteroids, estrogen, omega-3 fatty acids, S-adenosylmethionine, cannabinoids, piracetam, modafinil, L-theanine, bexarotene with neuroprotective properties is discussed. The mechanisms underlying the neuroprotective effects of these compounds vary and differ from classically defined dopamine and serotonin receptors. This review highlights selective evidence supporting a neuroprotective approach in the search for novel compounds, and suggests future directions for this exciting area. Neuroprotection strategy may be a useful paradigm for treatment of prodromal and first-episode schizophrenia patients and might have a significant impact on the subsequent course and outcome of the illness. The clinical effects of neuroprotective agents clearly merit further investigation in schizophrenia spectrum disorders. KeywordsSchizophrenia-Neurodevelopmental model-Neurodegenerative model-Apoptosis-Oxidative stress-Excitotoxicity-Stress sensitization-Neurotrophic factor expression-Alteration of neurosteroids-Vulnerability model-Neurocognitive domains-Quality of life deficit-Neuroprotective agents-Neurosteroids-Pregnenolone-Dehydroepiandrosterone-Bexarotene-Theanine
    12/2009: pages 343-395;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Indicated prevention is currently one of the most promising approaches to fight the individual and societal burden associated with psychosis and particularly schizophrenia. The number of studies is still limited, yet encouraging results have been reported from pharmacological and psychotherapeutic trials. Furthermore, it has become clear that persons characterized by the at-risk criteria are already ill and do not only need preventive intervention but also treatment. As is indicated by a recent study successfully using omega-3 fatty acids for both purposes, it may be promising to develop and investigate interventions especially for the at-risk state, independent of their effectiveness in manifest disease states. An overview on the current findings and ongoing research in this area is provided.
    European Archives of Psychiatry and Clinical Neuroscience 11/2010; 260 Suppl 2:S90-4. DOI:10.1007/s00406-010-0139-5 · 3.36 Impact Factor


Available from